secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056850
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma reports Q3 FY2024 cash $56.6M, no revenue; prioritizes voruciclib program
--------------------------------------------------------------------------------

- Cash, equivalents & investments $56.6M at Mar 31, 2024; no revenue for Q3 vs $5.9M prior year.
- R&D expenses $5.2M (down from $15.1M YoY) due to zandelisib wind-down; G&A $4.6M (down from $7.2M).
- Voruciclib Phase 1 expansion cohort enrolling; complete responses observed in R/R AML patients.
- Board unanimously prioritizes voruciclib, decides against second return of capital under cooperation agreement.
- ME-344 formulation development initiated; update expected in first half of calendar 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024056850/0000950170-24-056850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024056850/meip-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer